KING OF PRUSSIA, Pa., March 30, 2026 – SEED Therapeutics, Inc. (‘SEED’), a clinical-stage biotechnology firm focused on the development of molecular glue degraders, has announced its participation in the upcoming 2026 Annual Meeting of the American Association for Cancer Research (AACR). This significant event will be held from April 17 to 22, 2026, in San Diego, California.
Presentation Details
- Title: RBM39 Degrader Anticancer Activity Against Neuroblastoma; MYC and CDKN2A/B as Potential Response Biomarkers
- Presenter / Authors: James Finn, Imad Salhab, Haihong Jin, Fei Liu, Dong Liu, Yunkai Zhang, Xing Liu, James Tonra, Lan Huang, Dan Lu
- Presentation Time: April 21, 2026, 2PM to 5PM PT
- Location: Poster Section 15 at San Diego Convention Center
- Session Category: Experimental and Molecular Therapeutics
- Session Title: Proximity-Induced Drug Discovery 2
- Poster Board Number: 12
- Poster Number: 5785
About SEED Therapeutics
SEED Therapeutics is at the forefront of biotechnology, innovating in the field of targeted protein degradation to address challenges posed by diseases associated with undruggable proteins. The company employs its proprietary RITE3™ platform, which is designed to facilitate precise small-molecule interventions in protein degradation.
Founded by four prominent scientific figures, SEED Therapeutics benefits from a strong foundation in research and innovation:
- Prof. Avram Hershko, a Nobel Laureate and discoverer of the ubiquitin-proteasome system.
- Dr. Lan Huang, who resolved the first E3 Ligase structure and has extensive experience as a biotech entrepreneur.
- Prof. Ning Zheng from the University of Washington, an HHMI Investigator and pioneer in RING-finger E3 Ligase structures, who coined the term “molecular glue”.
- Prof. Michele Pagano, an HHMI Investigator and leading expert in E3 ligase biology at NYU Grossman School of Medicine.
Key collaborators and investors include Eli Lilly and Co. and Eisai Co., Ltd., both of which are integral to SEED’s mission to unlock the potential of previously elusive disease targets. The company’s research pipeline includes six molecular glue programmes that cover a range of therapeutic areas, including oncology, neurodegeneration, immunology, and virology.
For more information about funding opportunities in the field of biotechnology and drug discovery, please visit relevant resources such as Innovate UK or Horizon 2020.